US Patent Issued to PRILENIA NEUROTHERAPEUTICS, National University of Singapore, - AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH on Feb. 17 for "Use of pridopidine for the treatment of fragile X syndrome" (Israeli, Singaporean Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,551,474, issued on Feb. 17, was assigned to PRILENIA NEUROTHERAPEUTICS LTD. (Israel), National University of Singapore (Singapore) and - AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore).

"Use of pridopidine for the treatment of fragile X syndrome" was invented by Michael Hayden (Herzliya, Israel), Mahmoud Abdulhossein Pouladi (Singapore) and Michal Geva (Even-Yehuda, Israel).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pri...